Monday, September 06, 2021 11:34:30 AM
Great read. Seems like this company's been ultra-focused for a number of years in progressing their science forward. I sense this scientific team has been very committed and encouraged with the results of some of the preclinical work they've done.
Regen BioPharma, Inc. Receives Positive Data From Preclinical Studies of Its Small Molecule NR2F6 Modulators
https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Receives-Positive-Data-From-Preclinical-Studies-of-Its-Small-Molecule-NR2F6-Modulators?id=140872
“ I am not a financial advisor just a shareholder given my personal opinion.” I do not give financial advice nor do I advise or recommend anyone to take my opinions as financial advice”
Regen BioPharma, Inc. Receives Positive Data From Preclinical Studies of Its Small Molecule NR2F6 Modulators
https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Receives-Positive-Data-From-Preclinical-Studies-of-Its-Small-Molecule-NR2F6-Modulators?id=140872
“ I am not a financial advisor just a shareholder given my personal opinion.” I do not give financial advice nor do I advise or recommend anyone to take my opinions as financial advice”
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
